Interferon protects mice against inhalation anthrax

Journal of Interferon and Cytokine Research

Volumn 28, Issue 10, 2008, Pages 597-601

  Walberg, Kristin ^a   Baron, Samuel ^a   Poast, Joyce ^a   Schwartz, Barbara ^b,c   Izotova, Lara ^b,c   Pestka, Sidney ^b,c   Peterson, J W ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b PBL InterferonSource   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; INTERFERON RECEPTOR; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON;

ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERICIDAL ACTIVITY; DEATH; DOSE RESPONSE; DRUG ACTIVITY; IN VIVO STUDY; INHALATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTHRAX; BACILLUS ANTHRACIS; CARBOXYMETHYLCELLULOSE; INTERFERON INDUCERS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-GAMMA, RECOMBINANT; INTERFERONS; MICE; MICE, KNOCKOUT; POLY I-C; POLYLYSINE; RESPIRATORY TRACT INFECTIONS;

BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); MURINAE; MUS;

EID: 54349121628     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0143     Document Type: Article

References (21)

1. Altboum Z, Gozes Y, Barnea A, Pass A, White M, Kobiler D. 2002. Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect Immun 70:6231-6241.
2. Baron S, Madkan V, Lozano A, Poast JS, Guerrero-Plata A, Garofalo RP, Tyring SK. 2007. Biological basis of interferons' actions and uses. In Chadha KC, ed., Interferons: Current Status, 2007. Kerala, India: Research Signpost, Vol. 37/661: p. In Press.
3. Baron S, Weigent D, Stanton GJ, Peterson JW. 1985. The protective role of endogenous interferon in viral, bacterial, and protozoal infections. Antiviral Res Suppl 1:173-183.
4. Bekisz J, Schmeisser H, Hernandez J, Goldman ND and Zoon KC. 2004. Human interferons alpha, beta and omega. Growth Factors 22:243-251.
5. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. 2002. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:119-134.
6. Bogdan C. 2000. The function of type I interferons in antimicrobial immunity. Curr Opini Immunol 12:419-424.
7. Comer JE, Noffsinger DM, McHenry DJ, Weisbaum DM, Chatuev BM, Chopra AK, Peterson JW. 2006. Evaluation of the protective effects of quinacrine against Bacillus anthracis ames. J Toxicol Environ Health 69:1083-1095.
8. Dewan PK, Fry AM, Laserson K, Tierney BC, Quinn CP, Hayslett JA, Broyles LN, shane A, Winthrop KL, Walks I, Siegel L, Hales T, Semenova VA, Romero-Steiner S, Elie C, Khabbaz R, Khan AS, Hajjeh RA, Schuchat A, Washington DC, Anthrax Response Team. 2002. Inhalational anthrax outbreak among postal workers, Washington, DC, 2001. Emerg Infect Dis 8:1066-1072.
9. Giron DJ, Schmidt JP, Ball RJ, Pindak FF. 1972. Effect of interferon inducers and interferons on bacterial infections. Antimicrob Agents Chemother 1:80-81.
10. Gold JA, Hoshino Y, Hoshino S, Jones MB, Nolan A, Weiden MD. 2004. Exogenous gamma and alpha/beta interferon rescues human macrophages from cell death induced by Bacillus anthracis. Infect Immun 72:1291-1297.
11. Gold JA, Hoshino Y, Jones MB, Hoshino S, Nolan A, Weiden MD. 2007. Exogenous interferon-alpha and interferon-gamma increase lethality of murine inhalational anthrax. PLoS ONE 2:e736.
12. Guerrero-Plata A, Baron S, Poast JS, Adegboyega PA, Casola A, Garofalo RP. 2005. Activity and regulation of alpha interferon in respiratory syncytial virus and human metapneumovirus experimental infections. J Virol 79:10190-10199.
13. Heine HS, Bassett J, Miller L, Hartings JM, Ivins BE, Pitt ML, Fritz D, Norris SL, Byrne WR. 2007. Determination of antibiotic efficiency against Bacillus anthracis in a mouse aerosol challenge model. Antimicrob Agents Chemother 51:1371-1379.
14. Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Tapper M, Fisk TL, Zaki S, Popovic T, Meyer RF, Quinn CP, Harper SA, Fridkin SK, Sejvar JJ, Shepard CW, McConnell M, Guarner J, Shieh WJ, Malecki JM, Gerberding JL, Hughes JM, Perkins BA, Anthrax Bioterrorism Investigation Team. 2001. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 7:933-944.
15. Mancuso G, Midiri A, Biondo C, Beninati C, Zummo S, Galbo R, Tomasello F, Gambuzza M, Macri G, Ruggeri A, Leanderson T, Teti G. 2007. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J Immunol 178:3126-3133.
16. Muller U, Steinhoff U, Reis L, Hemmi S, Pavlovic J, Zinkermagel R, Aguet M. 1994. Functional role of Type I and Type II interferons in antiviral defense. Science 264:1918-1921.
17. Pang KR, Wu JJ, Huang DB, Tyring SK, Baron S. 2005. Biological and clinical basis for molecular studies of interferons. In Carr DJJ, ed., Methods in Molecular Medicine: Interferon Methods and Protocols. Totowa, NJ: Humana Press, Inc., Vol. 116, p. 1-23.
18. Pestka S. 2007. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 282:20047-20051.
19. Peterson JW, Comer JE, Noffsinger DM, Wenglikowski A, Walberg KG, Chatuev BM, Chopra AK, Stanberry LR, Kang AS, Scholz WW, Sircar J. 2006. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun 74:1016-1024.
20. Vietri NJ, Purcell BK, Lawler JV, Leffel EK, Rico P, Gamble CS, Twenhafel NA, Ivins BE, Heine HS, Sheeler R, Wright ME, Friedlander AM. 2006. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci USA 103:7813-7816.
21. Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM, Okada H. 2007. Toll-like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 5:10.